Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

• Published in: Journal of clinical oncology Vol. 37; no. 16; pp. 1391 - 1402
• Main Authors: Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M, Stilgenbauer, Stephan
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01.06.2019
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Disease Progression; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Male; Middle Aged; ORIGINAL REPORTS; Progression-Free Survival; Purines - administration & dosage; Purines - adverse effects; Quinazolinones - administration & dosage; Quinazolinones - adverse effects; Recurrence; Rituximab - administration & dosage; Rituximab - adverse effects; Time Factors; United States; United States; Europe
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.18.01460

A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.